Kolltan Pharmaceuticals

Kolltan Pharmaceuticals

Based: New Haven, CT
Raised: $25 million
Investors: HBM Partners AG

The scoop: Kolltan has been developing new oncology therapies based on the scientific work of Yale's Joseph Schlessinger, the co-founder of the company. The biotech has kept a low profile generally, but recently wooed Gerald McMahon, the Senior VP of oncology R&D at MedImmune, into the CEO's job. About 30 staffers are at work at the biotech, which has raised a total of some $75 million. Peter Hirth, the CEO at Plexxikon, sits on the board. The biotech is developing monoclonal antibodies that target receptor tyrosine kinases.

Kolltan Pharmaceuticals
Read more on

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.